Should I buy or sell Minerva Neurosciences stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" NERV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NERV, but not buy additional shares or sell existing shares. View NERV analyst ratings or view top-rated stocks .

What is Minerva Neurosciences' stock price target for 2024?

1 brokers have issued 12-month price targets for Minerva Neurosciences' shares. Their NERV share price targets range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 343.5% from the stock's current price. View analysts price targets for NERV or view top-rated stocks among Wall Street analysts .

How have NERV shares performed in 2024?

Minerva Neurosciences' stock was trading at $6.15 on January 1st, 2024. Since then, NERV shares have decreased by 59.7% and is now trading at $2.48. View the best growth stocks for 2024 here .

When is Minerva Neurosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our NERV earnings forecast .

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences, Inc. (NASDAQ:NERV) issued its quarterly earnings data on Thursday, February, 22nd. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by $0.31.

When did Minerva Neurosciences' stock split?

Minerva Neurosciences's stock reverse split on Tuesday, June 21st 2022. The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of Minerva Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO) , Sorrento Therapeutics (SRNE) , PTC Therapeutics (PTCT) , Immunomedics (IMMU) , VBI Vaccines (VBIV) , Dynavax Technologies (DVAX) , Gilead Sciences (GILD) , Moderna (MRNA) , T2 Biosystems (TTOO) and Advanced Micro Devices (AMD) .

How do I buy shares of Minerva Neurosciences?

Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NERV

Minerva Neurosciences (NERV) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free NERV Stock Alerts

$2.48

-0.02 (-0.80%)

(As of 04:00 PM ET)

Compare

Today's Range: $2.45
▼
$2.53
50-Day Range: $2.42
▼
$10.33
52-Week Range: $2.26
▼
$13.49

Volume: 11,384 shs
Average Volume: 106,129 shs
Market Capitalization: $17.34 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.00

Get Minerva Neurosciences alerts:

Minerva Neurosciences MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 343.5% Upside
$11.00 Price Target
Short Interest: Healthy
0.74% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.89
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($3.57) to ($4.54) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.11 out of 5 stars

Medical Sector

338th out of 911 stocks

Biotechnology Industry

9th out of 32 stocks

3.0

Analyst's Opinion

Consensus Rating
Minerva Neurosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Minerva Neurosciences has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.74% of the float of Minerva Neurosciences has been sold short.
Short Interest Ratio / Days to Cover
Minerva Neurosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Minerva Neurosciences has recently increased by 5.22%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Minerva Neurosciences does not currently pay a dividend.
Dividend Growth
Minerva Neurosciences does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Minerva Neurosciences has received a 71.85% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for Parkinsonism", "Clinical research services for schizophrenia", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Minerva Neurosciences is -0.89.

2.0

News and Social Media Coverage

News Sentiment
Minerva Neurosciences has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
Search Interest
Only 1 people have searched for NERV on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Minerva Neurosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Minerva Neurosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.40% of the stock of Minerva Neurosciences is held by insiders.
Percentage Held by Institutions
Only 34.56% of the stock of Minerva Neurosciences is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Minerva Neurosciences are expected to decrease in the coming year, from ($3.57) to ($4.54) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Minerva Neurosciences is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Minerva Neurosciences is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Minerva Neurosciences Stock (NASDAQ:NERV)

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

NERV Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NERV Stock News Headlines

April 12, 2024 | americanbankingnews.com

Minerva Neurosciences (NASDAQ:NERV) Shares Pass Below 200 Day Moving Average of $5.76

April 4, 2024 | msn.com

Prairie voles display signs of human-like depression, show promise as animal model

April 19, 2024 | Behind the Markets (Ad)

The #1 Opportunity of the decade?

It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.

March 31, 2024 | msn.com

New track and field season gives Minerva sprinter Kyleigh Lippincott a fresh start

March 14, 2024 | msn.com

Potts Point homelessness encampment moved on from Minerva-Metro Theatre site

March 14, 2024 | tmcnet.com

Minerva Named "One to Watch" in Chartis Financial Crime and Compliance 50 Rankings

March 13, 2024 | msn.com

Renovated Manti Temple, preserved Minerva Teichert murals ready for 3-week public open house

March 13, 2024 | tmcnet.com

Minerva Named Top AI & Data Product in the 2024 Product Awards

April 19, 2024 | Behind the Markets (Ad)

The #1 Opportunity of the decade?

It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.

February 27, 2024 | markets.businessinsider.com

Hold Rating on Minerva Neurosciences Amid FDA Setbacks and Financial Constraints

February 27, 2024 | finance.yahoo.com

Minerva schizophrenia drug rejected by FDA

February 27, 2024 | marketwatch.com

FDA Turns Away Minerva's Roluperidone Schizophrenia Drug

February 27, 2024 | morningstar.com

Minerva Neurosciences Shares Slide on Latest FDA Roluperidone Setback

February 27, 2024 | msn.com

Regulatory Setback For Minerva Neurosciences' Schizophrenia Treatment Candidate, FDA Asks For More Data

February 27, 2024 | msn.com

Minerva falls as FDA rejects schizophrenia therapy

February 27, 2024 | bizjournals.com

FDA rejects Burlington biotech’s schizophrenia drug, sends stock tumbling

February 27, 2024 | reuters.com

US FDA declines to approve Minerva Neurosciences' schizophrenia drug

February 27, 2024 | finance.yahoo.com

Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

February 25, 2024 | msn.com

REUTERS NEWS SCHEDULE AT 7:00 a.m. SGT /6:00 p.m. ET

February 22, 2024 | benzinga.com

2NERV : Minerva Neurosciences: Q4 Earnings Insights

February 22, 2024 | sfgate.com

Minerva Neurosciences: Q4 Earnings Snapshot

February 22, 2024 | finance.yahoo.com

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

February 22, 2024 | globenewswire.com

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

February 9, 2024 | seekingalpha.com

SUNW, NSTG and NERV among mid-day movers

February 7, 2024 | msn.com

Market Street Art Spot expands gallery and marks 13th anniversary in Minerva

January 31, 2024 | msn.com

Garth Evans set to become Minerva Local Schools' next athletic director

January 17, 2024 | msn.com

'His fight is our fight': Malvern, Minerva basketball players learn life lesson

See More Headlines

Receive NERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:NERV
CUSIP: N/A
CIK: 1598646
Web: www.minervaneurosciences.com
Phone: (617) 600-7373
Fax: N/A
Employees: 9
Year Founded: 2007

Price Target and Rating

Average Stock Price Target: $11.00
High Stock Price Target: $11.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +338.2%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.65)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-30,000,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -50.27%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.57
Quick Ratio: 12.58

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($4.07) per share
Price / Book: -0.62

Miscellaneous

Outstanding Shares: 6,990,000
Free Float: 6,545,000
Market Cap: $17.54 million
Optionable: Not Optionable
Beta: 0.21

Social Links

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Remy Luthringer Ph.D. (Age 63)
Executive Chairman & CEO
Comp: $853.58k
Mr. Geoffrey Robin Race F.C.M.A. (Age 63)
M.B.A., President
Comp: $628.46k
Mr. Frederick W. Ahlholm CPA (Age 58)
Senior VP, CFO & Secretary
Comp: $567.49k
Mr. Joseph Reilly (Age 49)
Senior VP & COO
Comp: $461k
Mr. William B. Boni (Age 72)
Vice President of Investor Relations & Corporate Communications
Prof. Michael Davidson M.D. (Age 74)
Chief Medical Officer
Comp: $657.47k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NERV Stock Analysis - Frequently Asked Questions

Should I buy or sell Minerva Neurosciences stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" NERV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NERV, but not buy additional shares or sell existing shares.
View NERV analyst ratings or view top-rated stocks.
What is Minerva Neurosciences' stock price target for 2024?: 1 brokers have issued 12-month price targets for Minerva Neurosciences' shares. Their NERV share price targets range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 343.5% from the stock's current price.
View analysts price targets for NERV or view top-rated stocks among Wall Street analysts.
How have NERV shares performed in 2024?: Minerva Neurosciences' stock was trading at $6.15 on January 1st, 2024. Since then, NERV shares have decreased by 59.7% and is now trading at $2.48.
View the best growth stocks for 2024 here.
When is Minerva Neurosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our NERV earnings forecast.

How were Minerva Neurosciences' earnings last quarter?: Minerva Neurosciences, Inc. (NASDAQ:NERV) issued its quarterly earnings data on Thursday, February, 22nd. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by $0.31.
When did Minerva Neurosciences' stock split?: Minerva Neurosciences's stock reverse split on Tuesday, June 21st 2022. The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.
What other stocks do shareholders of Minerva Neurosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).
How do I buy shares of Minerva Neurosciences?: Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NERV) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial